Slide 1: Investor Relations, February 28, 2023
February 28, 2023 Investor Relations
Slide 2: Forward-Looking Statements
© 2023 Omnicell, Inc. Forward - Looking Statements 2 This presentation contains “forward - looking statements” within the meaning of federal securities laws. These forward - looking sta tements include statements with respect to 2023 guidance, strategic and growth opportunities, other expectations a
Slide 3: Our Mission and Vision
© 2023 Omnicell, Inc. Our Mission Our Vision Deliver the most compelling automation and services that accelerate pharmacy perfection. Be the clinician’s most trusted partner for medication management. We are dedicated to continuously deliver innovative technology that helps our customers improve pat
Slide 4: Our Strategy
© 2023 Omnicell, Inc. Our Strategy Fundamentally transform the pharmacy care delivery model by delivering a set of services that touch the entire continuum of care, built on a single cloud platform. 4
Slide 5: Omnicell: Compelling Growth Opportunities
© 2023 Omnicell, Inc. Category creator transforming the pharmacy care delivery model Leading strategic partner to health systems in large and growing market segments with $90 Billion+ Total Addressable Market (TAM) 1 Resilient, long - term revenue growth accelerated by strong bookings, backlog and u
Slide 6: The Autonomous Pharmacy Framework – an Industry Vision
© 2023 Omnicell, Inc. The Autonomous Pharmacy Framework – an Industry Vision 6 1
Slide 7: Our Comprehensive Solutions Fundamentally Deliver Better Healthcare Value
© 2023 Omnicell, Inc. Central Pharmacy Dispensing Service Specialty Pharmacy Services EnlivenHealth ® Point of Care IV Compounding Central Distribution Inventory Management Retail Home Connected Intelligent Infrastructure Inpatient Outpatient IV Compounding Service Point of Care Inventory Optimizati
Slide 8: Leader in Large and Growing Segments
© 2023 Omnicell, Inc. 8 Leader in Large and Growing Segments 1. Represents estimated cumulative TAM over 10 years as of 5/31/2022 and includes the United States, UK&I, Germany, France, Spai n, Kingdom of Saudi Arabia and Australia/New Zealand. Omnicell is growing its leadership position across a pot
Slide 9: Multiple Growth Drivers
© 2023 Omnicell, Inc. Multiple Growth Drivers Revenue Growth Drivers Deep Customer Relationships & Robust Backlog • More than 150 of the top 300 U.S. health systems 1 in long - term sole - source agreements • Over 50,000 retail pharmacies and 75% of U.S. pharmacy patients interact with Omnicell solu
Slide 10: Advanced Services Accelerating Recurring Revenue Growth
Advanced Services Accelerating Recurring Revenue Growth 10 Advanced Services (% of Total Revenue) Leveraging established channels and strong customer relationships Strong demand driven by increasing provider digitization and need to evolve medication supply chain Omnicell’s cloud - based services de
Slide 11: SaaS and Software Subscriptions Model
© 2023 Omnicell, Inc. SaaS and Software Subscriptions Model YEAR 1 YEAR 2 YEAR 3 YEAR 4 – 5 YEAR 1 YEAR 2 YEAR 3 YEAR 4 – 7 Advanced Services Business Model — Customer Example End of year 7 Net sales type lease balance: $0 Transition to Advanced Services business model anticipated to provide: 1) Inc
Slide 12: Strong Balance Sheet
© 2023 Omnicell, Inc. Strong Balance Sheet Free cash flow projected to grow slower than EBITDA as Omnicell reinvests in the transformation to Advanced Services Liquidity and capital structure support growth strategy $32M $1,016M $554M $330M $2,211M $1,130M Cash and Cash Equivalents Total Assets Tota
Slide 13: Backlog ($Million)
© 2023 Omnicell, Inc. Backlog 1 ($Million) 13 1. Backlog is the dollar amount of bookings that have not yet been recognized as revenue. We consider backlog that is expected t o b e converted to revenues in more than twelve months to be long - term backlog. We believe a majority of long - term produc
Slide 14: Total Year Revenue Composition
© 2023 Omnicell, Inc. Total Year Revenue Composition 14 1. Connected Devices, Software Licenses, and other include, but are not limited to, XT Series automated dispensing systems and p rod ucts related to Central Pharmacy Dispensing Service and IV Compounding Service. 2. Includes Central Pharmacy Di
Slide 15: 2022 Financial Snapshot
© 2023 Omnicell, Inc. 2022 Financial Snapshot 15 Non - GAAP 4Q - 2022 TY - 2022 Results YoY Change (%) Results YoY Change (%) Total Revenues $298 Million - 4% $1,297 Million +14% Gross Margin % 45.3% - 450bps 47.8% - 300bps Operating Expenses $124 Million +7% $480 Million +23% EBITDA $26 Million - 5
Slide 16: 2023 Financial Guidance
© 2023 Omnicell, Inc. 2023 Financial Guidance 16 Q1 - 2023 TY - 2023 Bookings 1 Not Provided $1.000 - $1.100 Billion Total Revenues $ 273 - $283 Million $1.150 - $1.190 B illion Product Revenues $179 - $184 Million $740 - $760 Million Service Revenues $94 - $99 Million $410 - $430 Million Technical
Slide 17: A Better Way: Our ESG Strategy
© 2023 Omnicell, Inc. 17 A Better Way: Our Environmental, Social and Governance (ESG) Strategy Innovation Accelerating for Perfection Design, and deliver, our products to minimize environmental footprint while maximizing patient outcomes Environment Innovating for Energy Efficiency Actively contribu
Slide 18: A Better Way: ESG Strategy Roadmap
© 2023 Omnicell, Inc. A Better Way: ESG Strategy 18 Roadmap designed to create enduring long - term value for all of our stakeholders Significance of ESG Strategy to Omnicell Corporate Responsibility (CR), and the ESG strategy fostered within, is fundamental to our mission, vision, and values. Creat
Slide 19: A Better Way: Our ESG Strategy in Action
© 2023 Omnicell, Inc. 19 A Better Way: Our ESG Strategy in Action 1. Sustainalytics ESG Risk Rating Report published on 1/24/2023. 2. MSCI report published on 02/14/2023. 44% of Board are women or racially / ethnically diverse #1 position amongst peer table for lowest ESG risk according to Sustainal
Slide 20: We Expect that Omnicell is Positioned to Win
© 2023 Omnicell, Inc. We Expect that Omnicell is Positioned to Win Based on Our Belief that: 20 1. Represents estimated cumulative TAM over 10 years as of 5/31/2022 and includes the United States, UK&I, Germany, France, Spai n, Kingdom of Saudi Arabia and Australia/New Zealand.. Omnicell has the rig
Slide 21: Appendix
Appendix
Slide 22: Reconciliation of GAAP to Non-GAAP
© 2023 Omnicell, Inc. 22 Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) 2022 2021 2022 2021 297,674$ 311,034$ 1,295,947$ 1,132,018$ Acquisition accounting impact related to deferred revenues 40 685 903 780 297,714$ 311,719$ 1,296,850
Slide 23: Reconciliation of GAAP to Non-GAAP (continued)
© 2023 Omnicell, Inc. 23 (a) Tax effects calculated for all adjustments except share-based compensation expense, using an estimated annual effective tax rate of 21% for fiscal years 2022 and 2021. (b) For the year ended December 31, 2022, non-GAAP diluted shares exclude approximately 0.5 million sha
Slide 24: Reconciliation of GAAP to Non-GAAP
© 2023 Omnicell, Inc. 24 Omnicell, Inc. Reconciliation of GAAP to Non-GAAP (Unaudited, in thousands, except per share data and percentage) 2017 (a) 30,518$ Share-based compensation expense 21,857 Interest (income) and expense, net 6,072 Depreciation and amortization expense 51,511 Acquisition accoun
Slide 25: Slide 25